IL1A and vasculitis: These observations emphasize the role of IL-1B in the overall pathogenesis of KD vasculitis, providing additional mechanistic insight into elevated IL-1B production during KD and highlighting the need for phase III clinical trials with anti–IL-1 therapeutic agents, such as anakinra.